-
1Academic Journal
Συγγραφείς: A. A. Li, T. M. Geliashvili, A. A. Rumyantsev, A. I. Pronin, A. S. Krylov, O. D. Baranova, A. V. Parnas, V. S. Ilyakov, D. A. Vorobyeva, А. А. Ли, Т. М. Гелиашвили, А. А. Румянцев, А. И. Пронин, А. С. Крылов, О. Д. Баранова, А. В. Парнас, В. С. Ильяков, Д. А. Воробьева
Πηγή: Cancer Urology; Том 20, № 4 (2024); 98-103 ; Онкоурология; Том 20, № 4 (2024); 98-103 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: 177 Lu-ПСМА-617, metastatic castration-resistant prostate cancer, 177 Lu-PSMA-617, метастатический кастрационно-резистентный рак предстательной железы
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1818/1587; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1818/1514; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1818/1515; Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63. DOI:10.3322/caac.21834; Шахзадова А.О., Старинский В.В., Лисичникова И.В. Состояние онкологической помощи населению России в 2022 году. Сибирский онкологический журнал 2023;22(5):5–13. DOI:10.21294/1814-4861-2023-22-5-5-13; Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023. 239 с.; Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180–92. DOI:10.1111/j.1742-1241.2011.02799.x; Hofman M.S., Hicks R.J., Maurer T., Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics 2018;38(1):200–17. DOI:10.1148/rg.2018170108; Sartor O., de Bono J., Chi K.N. et al.; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385(12):1091–103. DOI:10.1056/NEJMoa2107322; Fallah J., Agrawal S., Gittleman H. et al. FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2023;29(9):1651–7. DOI:10.1158/1078-0432.CCR-22-2875; https://oncourology.abvpress.ru/oncur/article/view/1818
-
2Academic Journal
Συγγραφείς: E. A. Nikolaeva, A. S. Krylov, A. D. Ryzhkov, T. M. Geliashvili, A. V. Pavlova, A. Yu. Goryainova, R. A. Murashko, Е. А. Николаева, А. С. Крылов, А. Д. Рыжков, Т. М. Гелиашвили, А. В. Павлова, А. Ю. Горяинова, Р. А. Мурашко
Πηγή: Cancer Urology; Том 20, № 2 (2024); 74-86 ; Онкоурология; Том 20, № 2 (2024); 74-86 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: радионуклидная терапия, metastatic castration-resistant prostate cancer, quantitative single-photon emission computed tomography/computed tomography, radium-223 dichloride, radionuclide therapy, метастатический кастрационно-резистентный рак предстательной железы, количественная однофотонная эмиссионная компьютерная томография, совмещенная с компьютерной томографией, дихлорид радия-223
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1762/1547; Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI:10.1056/NEJMoa040720; Pezaro C., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65(2):270–3. DOI:10.1016/j.eururo.2013.10.055; Smith H.S. Painful osseous metastases. Pain Physician 2011;14(4):E373–403.; Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12(20 Pt 2):6243s–9s. DOI:10.1158/1078-0432.CCR-06-0931; Tait C., Moore D., Hodgson C. et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progressionfree and overall survival. BJU Int 2014;114(6b):E70–3. DOI:10.1111/bju.12717; Riihimäki M., Thomsen H., Brandt A. et al. What do prostate cancer patients die of? Oncologist 2011;16(2):175–81. DOI:10.1634/theoncologist.2010-0338; Cornford P., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017;71(4):630–42. DOI:10.1016/j.eururo.2016.08.002; Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. DOI:10.1056/NEJMoa1213755; Sartor O., Coleman R., Nilsson S. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15(7):738–46. DOI:10.1016/S1470-2045(14)70183-4; Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014; 15(12):1397–406. DOI:10.1016/S1470-2045(14)70474-7; Nilsson S., Cislo P., Sartor O. et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 2016;27(5):868–74. DOI:10.1093/annonc/mdw065; Parker C., Finkelstein S.E., Michalski J.M. et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol 2016;70(5):875–83. DOI:10.1016/j.eururo.2016.06.002; Николаева Е.А., Тарачкова Е.В., Шейх Ж.В. и др. Обзор методов визуализации для оценки ответа на лечение метастазов в костях при раке предстательной железы и молочной железы. Кремлевская медицина. Клинический вестник 2022;3:107–14. DOI:10.26269/tvby-7e26; Helyar V., Mohan H.K., Barwick T. et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 2010;37(4):706–13. DOI:10.1007/s00259-009-1334-3; Vogelzang N.J., Coleman R.E., Michalski J.M. et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin Genitourin Cancer 2017;15(1):42–52.e8. DOI:10.1016/j.clgc.2016.07.027; Etchebehere E.C., Araujo J.C., Fox P.S. et al. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med 2015;56(8):1177–84. DOI:10.2967/jnumed.115.158626; Ulmert D., Kaboteh R., Fox J.J. et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 2012;62(1): 78–84. DOI:10.1016/j.eururo.2012.01.037; Fosbøl M.Ø., Petersen P.M., Kjaer A., Mortensen J. 223Ra therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematologic toxicity. J Nucl Med 2018;59(4):596–602. DOI:10.2967/jnumed.117.195677; Shariftabrizi A., Kothari S., George S. et al. Optimization of radium-223 treatment of castration-resistant prostate cancer based on the burden of skeletal metastasis and clinical parameters. Oncologist 2023;28(3):246–51. DOI:10.1093/oncolo/oyac245; Николаева Е.А., Крылов А.С., Рыжков А.Д. и др. Количественная оценка методом ОФЭКТ/КТ эффективности радионуклидной терапии хлоридом радия-223 костных метастазов при метастатическом кастрационно-резистентном раке предстательной железы. Онкологический журнал: лучевая диагностика, лучевая терапия 2022;5(3):29–42. DOI:10.37174/2587-7593-2022-5-3-29-42; Shore N.D. Radium-223 dichloride for metastatic castrationresistant prostate cancer: the urologist’s perspective. Urology 2015;85(4):717–24. DOI:10.1016/j.urology.2014.11.031; Gillessen S., Omlin A., Attard G. et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015;26(8):1589–604. DOI:10.1093/annonc/mdv257; CTCAE. National Cancer Institute Enterprise Vocabulary Services website. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/About.html (accessed 15 December 2023).; Asselah J., Sperlich C. Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: questions of choice. Can Urol Assoc J 2013;7(1–2 Suppl 1):S11–7. DOI:10.5489/cuaj.274; Sathianathen N.J., Lamb A., Nair R. et al. Updates of prostate cancer staging: prostate-specific membrane antigen. Investig Clin Urol 2016;57(Suppl 2):S147–54. DOI:10.4111/icu.2016.57.S2.S147; Lowrance W.T., Roth B.J., Kirkby E. et al. Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol 2016;195(5):1444–52. DOI:10.1016/j.juro.2015.10.086; Parker C., Gillessen S., Heidenreich A., Horwich A. ESMO Guidelines Committee. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v69–77. DOI:10.1093/annonc/mdv222; Saad F., Chi K.N., Finelli A. et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015;9(3–4):90–6. DOI:10.5489/cuaj.2526; Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO 2021;11(3s2):540–55. DOI:10.18027/2224-5057-2021-11-3s2-33; Smith M., Parker C., Saad F. et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol 2019;20(10):e559]. Lancet Oncol 2019;20(3):408–19. DOI:10.1016/S1470-2045(18)30860-X; Choudhury A.D., Kwak L., Cheung A. et al. Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 2021;39(6_suppl):98. DOI:10.1200/JCO.2021.39.6_suppl.98; Sternberg C.N., Saad F., Graff J.N. et al. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Ann Oncol 2020;31(2):257–65. DOI:10.1016/j.annonc.2019.10.025; Carles J., Alonso-Gordoa T., Mellado B. et al. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: a single-arm phase II trial. Eur J Cancer 2022;173:317–26. DOI:10.1016/j.ejca.2022.06.057; Marshall C.H., Fu W., Wang H. et al. Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bonemetastatic castration-resistant prostate cancer. Clin Cancer Res 2021;27(6):1623–30. DOI:10.1158/1078-0432.CCR-20-4476; Morris M.J., Loriot Y., Sweeney C.J. et al. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/ randomised phase 2a trial. Eur J Cancer 2019;114:107–16. DOI:10.1016/j.ejca.2019.04.007; Darolutamide with radium-223 or placebo and the effect on radiological Progression-free survival for patients with mCSPC (CARE). ClinicalTrials.gov. ID NCT05771896. Available at: https://clinicaltrials.gov/study/NCT05771896; Kostos L., Buteau J.P., Yeung T. et al. AlphaBet: combination of radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med (Lausanne) 2022;9:1059122. DOI:10.3389/fmed.2022.1059122; Pezaro C.J., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65:270–3. DOI:10.1016/j.eururo.2013.10.055; Bosch D., van der Velden K.J.M., Oving I.M. et al. The impact of baseline PSMA PET/CT vs. CT on outcomes of Radium-223 therapy in mCRPC patients. Annals of Oncology 2023;34(Suppl 2): 987–8. DOI:10.1016/j.annonc.2023.09.2771; Carles J., Castellano D., Méndez-Vidal M.J. et al. Circulating tumor Cells as a biomarker of survival and response to Radium-223 therapy: experience in a cohort of patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2018;16(6):e1133–9. DOI:10.1016/j.clgc.2018.07.013; Iizuka J. Evaluating radium-223 response in metastatic castrationresistant prostate cancer with imaging. Asia Pac J Clin Oncol 2018;14(Suppl 5):16–23. DOI:10.1111/ajco.13058; Scher H.I., Morris M.J., Stadler W.M. et al. Prostate cancer clinical trials working group 3. Trial design and objectives for castrationresistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34(12):1402–18. DOI:10.1200/JCO.2015.64.2702; https://oncourology.abvpress.ru/oncur/article/view/1762
-
3Academic Journal
Συγγραφείς: B. Ya. Alekseev, Yu. V. Anzhiganova, A. V. Sultanbaev, A. A. Bystrov, A. S. Orlov, G. V. Gopp, A. V. Kopyltsov, A. V. Lykov, V. A. Atduev, G. N. Alekseeva, L. M. Rodygin, S. A. Varlamov, A. V. Shestakov, M. R. Maturov, M. F. Urmantsev, L. V. Lankina, E. L. Parsadanova, V. Yu. Startsev, O. V. Vedrova, S. Yu. Andreev, A. A. Perevoshchikov, O. A. Mailyan, A. S. Kalpinskiy, Б. Я. Алексеев, Ю. В. Анжиганова, A. B. Султанбаев, А. А. Быстров, А. С. Орлов, Г. В. Гопп, Е. И. Копыльцов, А. В. Лыков, В. А. Атдуев, Г. Н. Алексеева, Л. М. Родыгин, С. А. Варламов, А. В. Шестаков, М. Р. Матуров, М. Ф. Урманцев, Л. В. Ланкина, Э. Л. Парсаданова, В. Ю. Старцев, О. В. Ведрова, С. Ю. Андреев, А. А. Перевощиков, О. А. Маилян, А. С. Калпинский
Συνεισφορές: The study was performed with the support of AstraZeneca Pharmaceuticals., Исследование проведено при поддержке ООО «АстраЗенека Фармасьютикалз».
Πηγή: Cancer Urology; Том 20, № 2 (2024); 87-100 ; Онкоурология; Том 20, № 2 (2024); 87-100 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: молекулярно-генетический анализ, metastatic castration-resistant prostate cancer, homologous recombination, mutation of homologous recombination, new generation antiandrogen, next generation sequencing, molecular genetic analysis, метастатический кастрационно-резистентный рак предстательной железы, гомологичная рекомбинация, мутация генов гомологичной рекомбинации, антиандроген нового поколения, секвенирование нового поколения
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1836/1532; Злокачественные новообразования в России в 2022 году (забо леваемость и смертность). Под. ред. А.Д. Каприна, В.В. Ста ринского, О.В. Шахзадовой, И.В. Лисичниковой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Мин здрава России, 2023. 275 с.; Achard V., Putora P.M., Omlin A. et al. Metastatic prostate cancer: treatment options. Oncology 2022;100(1):48–59. DOI:10.1159/000519861; Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513–20. DOI:10.1056/NEJMoa041318; Tannock I.F., Osoba D., Stockler M.R. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756–64. DOI:10.1200/JCO.1996.14.6.1756; Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI:10.1056/NEJMoa040720; De Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomized openlabel trial. Lancet 2010;376(9747):1147–54. DOI:10.1016/S0140-6736(10)61389X; FDA approved enzalutamide. Reference ID 4291091. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203415s014lbl.pdf; Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138–48. DOI:10.1056/NEJMoa1209096; FDA approved abiraterone acetate. Reference ID 2939553 Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf; Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. DOI:10.1056/NEJMoa1213755; Sartor O., de Bono J., Chi K.N. et al. Lutetium177PSMA617 for metastatic castrationresistant prostate cancer. N Engl J Med 2021;385(12):1091–103. DOI:10.1056/NEJMoa2107322; Hussain M., Mateo J., Fizazi K. et al. Survival with olaparib in metastatic castrationresistant prostate cancer. N Engl J Med 2020;383(24):2345–57. DOI:10.1056/NEJMoa2022485; De Bono J., Mateo J., Fizazi K. et al. Olaparib for metastatic castration resistant prostate cancer. N Engl J Med 2020;382(22):2091–102. DOI:10.1056/NEJMoa1911440; Abida W., Campbell D., Patnaik A. et al. Rucaparib for the treatment of metastatic castrationresistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. Eur Urol 2023;84(3):321–30. DOI:10.1016/j.eururo.2023.05.021; Chi K.N., Rathkopf D., Smith M.R. et al. Niraparib and abiraterone acetate for metastatic castrationresistant prostate cancer. J Clin Oncol 2023;41(18):3339–51. DOI:10.1200/JCO.22.01649; De Bono J.S., Mehra N., Scagliotti G.V. et al. Talazoparib monotherapy in metastatic castrationresistant prostate cancer with DNA repair alterations (TALAPRO1): an openlabel, phase 2 trial [published correction appears in Lancet Oncol 2022;23(5):e207] [published correction appears in Lancet Oncol 2022;23(6):e249]. Lancet Oncol 2021;22(9):1250–64. DOI:10.1016/S14702045(21)003764; Agarwal N., Azad A.A., Carles J. et al. Talazoparib plus enzalutamide in men with firstline metastatic castrationresistant prostate cancer (TALAPRO2): a randomised, placebocontrolled, phase 3 trial [published correction appears in Lancet 2023;402(10398):290]. Lancet 2023;402(10398):291–303. DOI:10.1016/S01406736(23)010553; Castro E., Mateo J., Olmos D., de Bono J.S. Targeting DNA repair: the role of PARP inhibition in the treatment of castrationresistant prostate cancer. Cancer J 2016;22(5):353–6. DOI:10.1097/PPO.0000000000000219; Chung J.H., Dewal N., Sokol E. et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol 2019;3: PO.18.00283. DOI:10.1200/PO.18.00283; Cui M., Gao X.S., Gu X. et al. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer. Oncotarget 2017;8(25):40222–32. DOI:10.18632/oncotarget.16712; Maughan B.L., Munlde S., NematianSamani M. et al. Survival outcomes of APA as a starting treatment: impact in realworld patients with mCSPC (OASIS). J Clin Oncol 2024;42(4_suppl):65. DOI:10.1200/JCO.2024.42.4_suppl.6; https://oncourology.abvpress.ru/oncur/article/view/1836
-
4Academic Journal
Συγγραφείς: O. A. Mailyan, A. S. Kalpinskiy, I. V. Reshetov, Yu. V. Anzhiganova, K. M. Nyushko, А. D. Kaprin, M. P. Golovashchenko, S. P. Kokin, V. A. Stakanov, B. Ya. Alekseev, О. А. Маилян, А. С. Калпинский, И. В. Решетов, Ю. В. Анжиганова, К. М. Нюшко, А. Д. Каприн, М. П. Головащенко, С. П. Кокин, В. А. Стаканов, Б. Я. Алексеев
Συνεισφορές: The study was performed without external funding., Исследование проведено без спонсорской поддержки.
Πηγή: Cancer Urology; Том 18, № 3 (2022); 60-66 ; Онкоурология; Том 18, № 3 (2022); 60-66 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: мутации в российской популяции, metastatic castration-resistant prostate cancer, mutations in DNA repair genes, somatic mutations, mutations in the Russian population, метастатический кастрационно-резистентный рак предстательной железы, мутации в генах репарации ДНК, соматические мутации
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1570/1397; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.; Scher H.I., Morris M.J., Stadler W.M. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34(12):1402–18. DOI:10.1200/JCO.2015.64.2702; Oh M., Alkhushaym N., Fallatah S. et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate 2019;79(8):880–95. DOI:10.1002/pros.23795; De Bono J.S., Oudard S., Ozguroglu M. et al. 2010 Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–54. DOI:10.1016/S0140-6736(10)61389-X; Fizazi K., Shore N., Teuvo L. Tammela et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383(11):1040–9. DOI:10.1056/NEJMoa2001342; Smith M.R., Saad F., Chowdhury S. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408–18. DOI:10.1056/NEJMoa1715546; Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. DOI:10.1056/NEJMoa1207506; Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33. DOI:10.1056/NEJMoa1405095; Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI:10.1056/NEJMoa1704174; Ku S.Y., Gleave M.E., Beltran H. Towards precision oncology in advanced prostate cancer. Nat Rev Urol 2019;16(11):645–54. DOI:10.1038/s41585-019-0237-8; De Bono J., Mateo J., Fizazi K. et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382(22):2091–102. DOI:10.1056/NEJMoa1911440; Abida W., Patnaik A., Campbell D. et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 2020;38(32):3763–72. DOI:10.1200/JCO.20.01035; Abida W., Campbell D., Patnaik A. et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res 2020;26(11):2487–96. DOI:10.1158/1078-0432.CCR-20-0394; Abida W., Cheng M., Armenia J. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 2019;5(4):471–8. DOI:10.1001/jamaoncol.2018.5801; Alexeev B., Lyubchenko L., Gordiev M. et al. ADAM: a multicenter, non-interventional, prospective cohort study for determination of prevalence of homologous recombination repair genes mutations (HRRm) in metastatic castrate-resistant prostate cancer (mCRPC) – Interim analysis. J Clin Oncol 2022;40(6_suppl):169. DOI:10.1200/JCO.2022.40.6_suppl.169; Castro E., Romero-Laorden N., Del Pozo A. et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2019;37(6):490–503. DOI:10.1200/jco.18.00358; Abida W., Armenia J. et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017;2017:PO.17.00029. DOI:10.1200/PO.17.00029; De Bono J.S., Mateo J., Fizazi K. et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382:2091–102. DOI:10.1056/NEJMoa1911440; De Bono J.S., Fizazi K., Saad F. et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Annal Oncol 2019;30(suppl_5):v325–55. DOI:10.1093/annonc/mdz248; https://oncourology.abvpress.ru/oncur/article/view/1570
-
5Academic Journal
Συγγραφείς: O. A. Mailyan, A. S. Kalpinskiy, I. V. Reshetov, K. M. Nyushko, B. Ya. Alekseev, S. P. Kokin, V. A. Stakanov, M. P. Golovashchenko, О. А. Маилян, А. С. Калпинский, И. В. Решетов, К. М. Нюшко, Б. Я. Алексеев, С. П. Кокин, В. А. Стаканов, М. П. Головащенко
Πηγή: Cancer Urology; Том 17, № 1 (2021); 82-88 ; Онкоурология; Том 17, № 1 (2021); 82-88 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: герминальные мутации, metastatic castration-resistant prostate cancer, mutations in DNA repair genes, PARP inhibitor, somatic mutations, germline mutations, метастатический кастрационно-резистентный рак предстательной железы, мутации в генах репарации ДНК, PARP-ингибитор, соматические мутации
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1432/1252; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 250 с.; Lang S.H., Swift S.L., White H. et al. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol 2019;55(3):597-616. DOI:10.3892/ijo.2019.4842.; Castro E., Mateo J., Olmos D. et al. Targeting DNA repair: the role of parp inhibition in the treatment of castrationresistant prostate cancer. Cancer J 2016;22(5):353-6. DOI:10.1097/PPO.0000000000000219.; Robinson D., van Allen E.M., Wu Y.M. et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215-28. DOI:10.1016/j.cell.2015.05.001.; Chung J.H., Dewal N., Sokol E. et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol 2019;3:PO.18.00283. DOI:10.1200/PO.18.00283.; Abida W., Armenia J., Gopalan A. et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017;2017:PO.17.00029. DOI:10.1200/PO.17.00029.; Caldecott K.W. Single-strand break repair and genetic disease. Nat Rev Genet 2008;9(8):619-31. DOI:10.1038/nrg2380.; Hoeijmakers J.H. DNA damage, aging, and cancer. N Engl J Med 2009;361(15):1475-85. DOI:10.1056/NEJMra0804615.; Clancy S. Genetic Recombination. Nat Educat 2008;1(1):41.; Burkle A., Virag L. Poly(ADP-ribose): PARadigms and PARadoxes. Mol Aspects Med 2013;34(6):1046-65. DOI:10.1016/j.mam.2012.12.010.; Литвинов С.В. Основные пути репарации двойных разрывов геномной ДНК и взаимодействия между ними. Цитология и генетика 2014;48(3):64-77.; Heeke A.L., Pishvaian M.J., Lynce F. et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol 2018;2018:PO.17.00286. DOI:10.1200/PO.17.00286.; Langelier M.F., Eisemann T., Riccio A.A. et al. PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr Opin Struct Biol 2018;53:187-98. DOI:10.1016/j.sbi.2018.11.002.; Caffo O., Veccia A., Kinspergher S. et al. Aberrations of DNA repair pathways in prostate cancer: future implications for clinical practice? Front Cell Dev Biol 2018;6:71. DOI:10.3389/fcell.2018.00071.; Rouleau M., Patel A., Hendzel M.J. et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10(4):293-301. DOI:10.1038/nrc2812.; Virtanen V., Paunu K., Ahlskog J.K. et al. Rationale and current clinical development. Genes (Basel) 2019;10(8):565. DOI:10.3390/genes10080565.; Cook S.A., Tinker A.V. PARP Inhibitors and the evolving landscape of ovarian cancer management: a review. BioDrugs 2019;33(3):255-73. DOI:10.1007/s40259-019-00347-4.; Keung M.Y.T., Wu Y., Vadgama J.V. PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers. J Clin Med 2019;8(4):435. DOI:10.3390/jcm8040435.; Kote-Jarai Z., Leongamornlert D., Saunders E. et al. BRCA2 is a moderate penetrance gene contributing to youngonset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011;105(8):1230-4. DOI:10.1038/bjc.2011.383.; Antoniou A., Pharoah P.D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117-30. DOI:10.1086/375033.; Swift S.L., Lang S.H., White H. et al. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review. Future Oncol 2019;15(28):3283-303. DOI:10.2217/fon-2019-0298.; Edwards S.M., Evans D.G., Hope Q. et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010;103(6):918-24. DOI:10.1038/sj.bjc.6605822.; Матвеев В.Б., Киричек А.А., Савинкова А.В. и др. Влияние герминальных мутаций в гене CHEK2 на выживаемость до биохимического рецидива и безметастатическую выживаемость после радикального лечения у больных раком предстательной железы. Онкоурология 2018;14(4):53-67. DOI:10.17650/1726-9776-2018-14-4-53-67.; Fachal L., Gomez-Caamano A., Celeiro-Munoz C. et al. BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data. Prostate 2011;71(16):1768-79. DOI:10.1002/pros.21394.; Cui M., Gao X.S., Gu X. et al. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer. Oncotarget 2017;8(25):40222-32. DOI:10.18632/oncotarget.16712.; Oh M., Alkhushaym N., Fallatah S. et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate 2019;79(8):880-95. DOI:10.1002/pros.23795.; NCCN Guideline with Evidence Blocks - Prostate Cancer Version 2.2021. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf.; Pritchard C.C., Mateo J., Walsh M.F. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375(5):443-53. DOI:10.1056/NEJMoa1603144.; Castro E., Romero-Laorden N., Del Pozo A. et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2019;37(6):490-503. DOI:10.1200/JCO.18.00358.; Матвеев В.Б., Киричек А.А., Филиппова М.Г. и др. Влияние герминальных мутаций в генах BRCA2 и CHEK2 на время до развития кастрационной резистентности у больных метастатическим гормоночувствительным раком предстательной железы. Урология 2019;(5):79-85. DOI: https://dx.doi.org/10.18565/urology.2019.5.79-85.; Kaufman B., Shapira-Frommer R., Schmutzler R.K. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33(3):244-50. DOI:10.1200/JCO.2014.56.2728.; Mateo J., Carreira S., Sandhu S. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373(18):1697-708. DOI:10.1056/NEJMoa1506859.; Mateo J., Porta N., Bianchini D. et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21(1):162-74. DOI:10.1016/S1470-2045(19)30684-9.; Abida W., Patnaik A., Campbell D. et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 2020;38(32):3763-72. DOI:10.1200/JCO.20.01035.; Smith M.R., Sandhu S.K., Kelly W.K. et al. Pre-specified interim analysis of GALAHAD: a phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Annal Oncol 2019;30(suppl_5):v851-934. DOI:10.1093/annonc/mdz394.; de Bono J., Mateo J., Fizazi K. et al. Olaparib for metastatic castrationresistant prostate cancer. N Engl J Med 2020;382(22):2091-102. DOI:10.1056/NEJMoa1911440.; https://oncourology.abvpress.ru/oncur/article/view/1432
-
6Academic Journal
Συγγραφείς: V. B. Matveev, A. S. Markova, В. Б. Матвеев, А. С. Маркова
Πηγή: Cancer Urology; Том 16, № 4 (2020); 129-135 ; Онкоурология; Том 16, № 4 (2020); 129-135 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: доцетаксел, metastatic castration-resistant prostate cancer, routine clinical practice, abiraterone, enzalutamide, docetaxel, метастатический кастрационно-резистентный рак предстательной железы, реальная клиническая практика, абиратерон, энзалутамид
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1413/1223; Bubendor F.L., Schopfer A., Wagner U. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31(5):578-83. DOI:10.1053/hp.2000.6698.; Pezaro C., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65(2):270-3. DOI:10.1016/j.eururo.2013.10.055.; Mottet N., Cornford P., van der Bergh R.C.N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer (2020). Available at: https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO-ESUR-SIOG-Guidelines-on-Prostate-Cancer-2020v4.pdf.; Schaeffer E., Srinivas S., Antonarakis E. et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) -prostate cancer (version 3.2020) (2020). Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.; Клинические рекомендации Ассоциации онкологов России по лечению пациентов с раком предстательной железы 2020. Доступно по: https://oncology-association.ru/wp-content/uploads/2020/09/rak_predstatelnoj_zhelezy.pdf.; Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23. DOI:10.1056/NEJMoa1213755.; Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castrationresistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, doubleblind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397-406. DOI:10.1016/S1470-2045(14)70474-7.; Saad F., Carles J., Gillessen S. et al. Radium-223 and concomitant therapies in patients with metastatic castrationresistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17(9):1306-16. DOI:10.1016/S1470-2045(16)30173-5.; Higano C.S., Saad F., Sartor A.O. et al. Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020;38(6_suppl):32. DOI:10.1200/JCO.2020.38.6_suppl.32.; Клинические рекомендации «Рак предстательной железы» Минздрава России 2020. Доступно по: http://cr.rosminzdrav.ru/#!/recomend/99.; Higano C.S., Harshman L.C., Dizdarevic S. et al. Safety and overall survival (OS) in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy. J Clin Oncol 2020;38 (15_suppl):5542.; Dizdarevic S., Petersen M.D., Essler M. et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in nonintervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imag 2019;46:1102-10. DOI:10.1007/s00259-019-4261-y.; Smith M., Parker C., Saad F. et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):408-19. DOI:10.1016/S1470-2045(18)30860-X.; European Medicines Agency (EMA). EMA restricts use of prostate cancer medicine Xofigo. 2018. Available at: https://www.ema.europa.eu/en/news/ema-restricts-use-prostate-cancer-medicine-xofigo.; Shore N.D., Tutrone R.F., Mariados N.F. et al. eRADicAte: a prospective evaluation combining radium-223 dichloride and abiraterone acetate plus prednisone in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2018;16(2):149-54. DOI:10.1016/j.clgc.2017.10.022.; Shore N., Higano C.S., George D.J. et al. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2020;23:680-8. DOI:10.1038/s41391-020-0236-0.; Poeppel T., Eschmann S., Werner A. et al. 828 P Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): an interim review of a prospective, noninterventional study (PARABO). Annal Oncol 2020;29(Suppl 8):VIII289-90. DOI:10.1093/annonc/mdy284.037.; Sternberg C.N., Saad F., Graff J.N. et al. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Ann Oncol 2020;31(2):257-65. DOI:10.1016/j.annonc.2019.10.025.; Sartor O., Vogelzang N.J., Sweeney C. et al. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an expanded access program. Oncologist 2018;23(2):193-202. DOI:10.1634/theoncologist.2017-0413.; https://clinicaltrials.gov/ct2/show/NCT02194842.; https://clinicaltrials.gov/ct2/show/NCT03574571.; https://oncourology.abvpress.ru/oncur/article/view/1413
-
7Academic Journal
Συγγραφείς: Тищенко В.К., Власова О.П., Лебедева А.А., Федорова А.В., Панкратов А.А., Морозова Н.Б., Кузенкова К.А., Степченкова Е.Д., Шегай П.В., Иванов С.А., Каприн А.Д.
Πηγή: Byulleten Eksperimentalnoi Biologii i Meditsiny
Θεματικοί όροι: prostate-specific membrane antigen, metastatic castrate-resistant prostate cancer, radioligand therapy, lutetium-177, radiopharmaceutical, простатспецифический мембранный антиген, метастатический кастрационно-резистентный рак предстательной железы, радиолигандная терапия, лютеций-177, радиофармпрепарат
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/104125/
-
8Academic Journal
Συγγραφείς: Крылов В.В., Легкодимова Н.С., Кочетова Т.Ю., Петриев В.М., Сигов М.А., Тищенко В.К., Пронин А.И., Шуринов А.Ю., Петросян К.М., Спиченкова О.Н., Карякин О.Б., Бирюков В.А., Степаненко В.Ф., Власова О.П., Шегай П.В., Иванов С.А., Каприн А.Д.
Πηγή: Лучевая диагностика и терапия
Θεματικοί όροι: metastatic castration-resistant prostate cancer, radionuclide therapy, radioligand therapy, radiopharmaceutical, 177 Lu-DOTA-PSMA, метастатический кастрационно-резистентный рак предстательной железы, радионуклидная терапия, радиолигандная терапия, радиофармпрепарат, 177 Lu-ДОТА-ПСМА
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/98653/